Table 1.
Baseline characteristics of IPF patients
| Trait | Value | MISSING, (%) | |
|---|---|---|---|
| N | 266 | ||
| MALE (%) | 64% | ||
| Age, years | 74.3 ± 8.45 | ||
| Follow-up time, years | 3.03 ± 2.97 | ||
| FVC % predicted | 77 ± 20 | 7% | |
| DLCO (mmol/min*kPa) | 4.02 ± 1.27 | 49% | |
| BMI kg/m2* | 27.8 ± 4.9 | 14% | |
| Charlson index | 2.1 ± 1.45 | ||
| Baseline 6 min walking test (m) | 335 ± 139 | 80% | |
| Any 6 min walking test (m)** | 349 ± 136 | 65% | |
| Baseline FVC | FVC>90% pred.; N (%) FVC % predicted |
64 (24%) 102 ± 10 |
|
| FVC 50-90% pred.; N (%) FVC % predicted |
167 (63%) 72 ± 11 |
||
| FVC <50% pred.; N (%) FVC % predicted |
17 (6%) 39 ± 8 |
||
| FVC unknown; N (%) FVC % predicted |
18 (7%) NA |
||
| Baseline smoking status * | Former, (%) | 31% | |
| Current smoker, (%) | 20% | ||
| Never smoked, (%) | 41% | ||
| Smoking status unknown, (%) | 9% | ||
| End of follow up type | Alive 31.12.2017, (%) | 41% | |
| Antifibrotic medication initiated, (%) | 16% | ||
| Dead, (%) | 42% | ||
*text-mined. Data presented as mean±SD if not otherwise indicated; **complementing baseline data with data from any time during follow-up; value closest to baseline used if multiple values were present